Emory University: Lymphoma trials
The registry lists 12 Lymphoma studies with Emory University as lead sponsor. 0 are open to participants now and 4 have results posted.
Early Phase 1 1Phase 1 5Phase 2 6No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
- Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell CollectionCompletedNCT01095757Phase 2Results posted
- A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
- Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and RituximabTerminatedNCT00208975Phase 2Results posted
- Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell TransplantationActive, not recruitingNCT06328699Not applicable
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
- Improving Patient Education for Lymphoma and Leukemia InpatientsCompletedNCT02642510Not applicable
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)TerminatedNCT01005979Phase 1
- Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's DiseaseTerminatedNCT00209014Phase 2